The endothelin-1 antagonist, atrasentan, improves time to progression and quality of life in hormone-refractory prostate cancer.
Fisher
Maxine
M
D000284:Administration, Oral; D000368:Aged; D018931:Antineoplastic Agents, Hormonal; D000077868:Atrasentan; D018450:Disease Progression; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D019008:Drug Resistance, Neoplasm; D019332:Endothelin-1 / Q000037:antagonists & inhibitors*; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D009367:Neoplasm Staging; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D011759:Pyrrolidines / Q000008:administration & dosage*; D011788:Quality of Life; D018570:Risk Assessment; D016896:Treatment Outcome
D018931:Antineoplastic Agents, Hormonal; D019332:Endothelin-1; D011759:Pyrrolidines; D000077868:Atrasentan